All News

#ACR21 Abs#1425. AURORA2 - voclosporin for LN extension ⭐️216/357 pts continued into 2-yr study ⭐️Mean UPCR at month 30: 0.58 in VOC vs 1.3 control. eGFR ⬇️ in VOC, remains stable ⭐️No new AEs @Rheumnow https://t.co/m5bl9Ho163 https://t.co/VVGOCd9vmC

Links:

Eric Dein ericdeinmd ( View Tweet)
What better than a tweet on a #ACR21 study of tweets! 😂 Using Twitter Firehose data stream - yes we should do a study just during the ACR week...! Fake tweets exists but low in the rheumatology community! @rheumnow #abst1068 Paper - https://t.co/ekguL5qXen https://t.co/rfy7vZlXOn

Links:

Bella Mehta bella_mehta ( View Tweet)
Abst1356 #acr21 @RheumNow TNFi vs SEC in active US confirmed enthesitis: mean ActiveMASEI score ⬇️ 4.37 w/TNFi vs 2.22 secukinumab (p = 0.030). Secucinumab leads in regards to the PASI & DLQI score with Sec vs TNFi ( 3.44 vs 1.03 p = 0.001 & 5.57 vs 1.35 p = 0.005 respectively https://t.co/fGTxzvGY99
Olga Petryna DrPetryna ( View Tweet)
FDA Safety Update - Questions for Dr. Nikolov, Habal, Golding, Rajpal - Do we need post marketing RCTs BARI and UPA: one in prog for BARI, not for UPA - 1133, why high CI of 1.8? Based on stricter margins based on prior studies with diabetes - Are Tyk2 a worry? to early -#ACR21

Dr. John Cush RheumNow ( View Tweet)

FDA Safety Update - Questions for Dr. Nikolov, Habal, Golding, Rajpal - Bari OK in COVID but now CV risk: theres a limit (14d) for Bari in COVID - CV Risk applied to all JAKi - largely because all have same indication, same populations at risk #ACR21

Dr. John Cush RheumNow ( View Tweet)

FDA update - the safety of XIAFLEX injections (collagenase for Dupytrens) under review #ACR21 https://t.co/KOP3P8ASqN
Dr. John Cush RheumNow ( View Tweet)
Excellent Rheum Pearls session w/ Drs. Kolfenbach & Stone: 🔘⬆️CRP in SLE:: think infection not flare 🔘Ferritin:ESR ratio differentiate JIA flares from MAS 🔘Dilated capillaries at eyelid margin in JDM = disease activity 🔘Auscultate Back for bruits in TAK #ACR21 https://t.co/3pUOhYR3L2
Alicia Hinze alicia_hinze ( View Tweet)
@jaymehtamd When to escalate #MISC Tx @jaymehtamd #PedsRheum #ACR21 📌fever, cardiac dysfunction, ventilatory support, altered mental status, MAS, organ-threatening 📌Anakinra vs Tocilizumab vs Infliximab 📌Anticoagulation https://t.co/jkQUWYaOkT
Herman Tam DrPedsRheum ( View Tweet)
FDA Update: FDA timeline for revision of the labels for TOFA, BARI, UPA - all needing to add a boxed warning on CV and cancer risk - This could take 2-3 mos- This is why youre still waiting.. #ACR21 https://t.co/DfJWWYuUQh
Dr. John Cush RheumNow ( View Tweet)
FDA Safety Update on JAK Inhibitors - bottom line on the Tofactitinib Post-Marketing (PMR) study published Sept 1st (cancer higher rates of lung CA and lymphoma with both doses of Tofa vs TNFi) #ACR21 https://t.co/UGbiTGVpgW
Dr. John Cush RheumNow ( View Tweet)

GOSH and NAC pedi CAPS pts study since 2005: anti-IL1 treatment has major impact on prevention and tx of CAPS symptoms. Observed by improved CAPS clinical dz activity scores; and normalized inflammatory markers. Abs 1110 #ACR21 #RheumNow @RheumNow https://t.co/xXrnVeRAq5

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

ASAS PerSpA study findings: rheumatologists tended to dx IBD-SpA in pts w peripheral arthritis more commonly than axial symptoms. IBD predominantly presenting symptoms. Abs 1310 #ACR21 #RheumNow @RheumNow https://t.co/Gq1b5gXn0v https://t.co/oZRvwvgbJD

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Abstr 1313 Lee & Colleagues used clustering analysis to study impact of comorbidities in patients with #axSpA - Comorbidities can influence treatment outcomes and should be accounted for in when treating #axSpA #ACR21 @RheumNow https://t.co/rN7LPQ9qEk
Akhil Sood MD AkhilSoodMD ( View Tweet)
Clinical Pearl from Dr. @JKolfenbach: ⭐️(-) ANCA doesn't r/o limited GPA ⭐️Biopsies can be just as important for ruling out mimics: ‣Neoplastic Dx (NK/T cell sinus lymphomas) ‣Histiocytic process ‣Infectious (fungal, mycobacteria) ‣Foreign material (cocaine) #ACR21 @RheumNow https://t.co/PEoYPBFLj0
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#Precisionmedicine is here but we’re not using it? A 23 molecular signature response classifier (MSRC) identified pts w RA unlikely to respond to #TNFi. no response was<ACR50 over 1yr. 175 w 26⬆️MSRC & 47 ⬆️⬆️MSRC. If ⬇️MSRC29%<ACR50 v 42&60%. ?cost Abst#1252 #ACR21 @RheumNow https://t.co/xdYyN0oXrh
Janet Pope Janetbirdope ( View Tweet)
Abst1100 #ACR2021 @RheumNow PAH in AOSD rare, mostly in polycyclic disease, associated w/flares (85%). overall survival 93% at 1 year and 74% at 3 years. PAH was severe at diagnosis: 2 (15%), 7 (54%) and 4 (31%) patients were in NYHA functional class II, III and IV, respectively. https://t.co/x20LooA2G7
Olga Petryna DrPetryna ( View Tweet)
Always thought⬆️health care access in Canada would lead to⬆️utilization of arthroplasty also rich-poor differences would be lower due to universal health access. Our study Canada Vs US and says otherwise!! Rich-poor differences are📈 greater in Canada! @rheumnow #abst1037 #ACR21 https://t.co/wKHXpsgSJn
Bella Mehta bella_mehta ( View Tweet)
While outcomes didn't worsen, de novo PsO can occur at any time point in axSpA (results per 6 year, DESIR cohort study.) Regular follow ups are key to monitoring. Abs 1311 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/X1bot5UJ6Q https://t.co/qfbDhCT9q5

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Well, this just got fun. Let's follow this, blow by blow in this thread. @US_FDA session #ACR21 @RheumNow https://t.co/3GCRfsINgn
David Liew drdavidliew ( View Tweet)
Abstr 1317 Impact of Memory in #axSpA Compared to healthy controls, patients with #axSpA performed significantly worse on Memory and Attention Test (MAT) specifically in working memory and selective attention #ACR21 @RheumNow https://t.co/PJS2QroKOS
Akhil Sood MD AkhilSoodMD ( View Tweet)
×